AU2002236489A1 - Reduction of antioxidant enzyme levels in tumor cells using antisense oligonucleotides - Google Patents

Reduction of antioxidant enzyme levels in tumor cells using antisense oligonucleotides

Info

Publication number
AU2002236489A1
AU2002236489A1 AU2002236489A AU3648902A AU2002236489A1 AU 2002236489 A1 AU2002236489 A1 AU 2002236489A1 AU 2002236489 A AU2002236489 A AU 2002236489A AU 3648902 A AU3648902 A AU 3648902A AU 2002236489 A1 AU2002236489 A1 AU 2002236489A1
Authority
AU
Australia
Prior art keywords
reduction
tumor cells
antisense oligonucleotides
enzyme levels
antioxidant enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002236489A
Inventor
Larry Wayne Oberley
Benjamin Barnes Smith
Christine J. Weydert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation UIRF
Original Assignee
University of Iowa Research Foundation UIRF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Iowa Research Foundation UIRF filed Critical University of Iowa Research Foundation UIRF
Publication of AU2002236489A1 publication Critical patent/AU2002236489A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01006—Catalase (1.11.1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01009—Glutathione peroxidase (1.11.1.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
AU2002236489A 2000-11-14 2001-11-14 Reduction of antioxidant enzyme levels in tumor cells using antisense oligonucleotides Abandoned AU2002236489A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24832800P 2000-11-14 2000-11-14
US60/248,328 2000-11-14
PCT/US2001/044241 WO2002040498A2 (en) 2000-11-14 2001-11-14 Reduction of antioxidant enzyme levels in tumor cells using antisense oligonucleotides

Publications (1)

Publication Number Publication Date
AU2002236489A1 true AU2002236489A1 (en) 2002-05-27

Family

ID=22938630

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002236489A Abandoned AU2002236489A1 (en) 2000-11-14 2001-11-14 Reduction of antioxidant enzyme levels in tumor cells using antisense oligonucleotides

Country Status (3)

Country Link
US (1) US20020156040A1 (en)
AU (1) AU2002236489A1 (en)
WO (1) WO2002040498A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2221376B1 (en) 2001-06-21 2012-11-21 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US20050019915A1 (en) 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
MX2016012922A (en) 2014-04-01 2017-01-26 Ionis Pharmaceuticals Inc Compositions for modulating sod-1 expression.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein

Also Published As

Publication number Publication date
US20020156040A1 (en) 2002-10-24
WO2002040498A2 (en) 2002-05-23
WO2002040498A3 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
AU2001254885A1 (en) Modified ES cells and ES cell-specific gene
AU4193700A (en) Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
AU1954001A (en) Methods for high level expression of genes in primates
AU3316600A (en) Gene expression in bladder tumors
AU2778801A (en) Antisense compositions and methods
AU6750800A (en) Methods of inhibiting cancer cells with adnf III antisense oligonucleotides
AU2001260847A1 (en) Compositions isolated from skin cells and methods for their use
AU2309700A (en) Oligonucleotide array and methods of use
AU2001245987A1 (en) Compositions and methods for gene therapy
AU1453301A (en) Methods of reversing drug resistance in cancer cells
AU2002356898A1 (en) Gene amplification and overexpression in cancer
AU4224999A (en) Antisense oligonucleotide modulation of human thymidylate synthase expression
AU4009899A (en) Molecules targeting cd40 and tumor cells
AU2881301A (en) Cancer cell implantation inhibitors
GB9916790D0 (en) Storage of microorganisms,cells and tissue
AU2001234544A1 (en) Novel human protein kinases and protein kinase-like enzymes
AU2001251138A1 (en) Compositions and methods for tissue specific gene regulation therapy
AU2002236489A1 (en) Reduction of antioxidant enzyme levels in tumor cells using antisense oligonucleotides
AU2002224096A1 (en) Method of testing anticancer agent-sensitivity of tumor cells
AU8026300A (en) Sodd gene expression in cancer
AU2001269803A1 (en) Compositions and methods for modulating muscle cell and tissue contractility
AU2001269081A1 (en) Electrochemical cells
AU2153401A (en) Gene expression in biological conditions
AU4771600A (en) Cells, culture methods and their uses
AU2001296412A1 (en) Antisense modulation of mekk4 expression